BTTX | Better Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0001 - 0.0001
52 Week Range	0.0001 - 0.5300
Beta	1.17
Implied Volatility	579.22%
IV Rank	19.68%
Day's Volume	200
Average Volume	163,082
Shares Outstanding	54,515,600
Market Cap	5,452
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-03-17

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-1.10
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	54
Country	USA
Website	BTTX

Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.

BTTX's peers: ADIL, BCDA, ABVC, FBRX, INDP, KTTA, LGVN, NNVC, RNXT, SEEL, VTGN, XRTX

*Chart delayed

Analyzing fundamentals for BTTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BTTX Fundamentals page.

Watching at BTTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BTTX Technicals page.